Levetiracetam-induced psychosis in a Filipino female diagnosed with anti-N-methyl-D-aspartate receptor encephalitis: a case report

Myrelle Frances F. Isidoro; Marissa T. Ong; Renato S. Dejan Jr

doi:10.18203/2320-6012.ijrms20232441

Authors

Myrelle Frances F. Isidoro Department of Neurosciences, Department of Health East Avenue Medical Center, Diliman, Quezon City, Philippines
Marissa T. Ong Department of Neurosciences, Department of Health East Avenue Medical Center, Diliman, Quezon City, Philippines
Renato S. Dejan Jr Department of Neurosciences, Department of Health East Avenue Medical Center, Diliman, Quezon City, Philippines

DOI:

https://doi.org/10.18203/2320-6012.ijrms20232441

Keywords:

LEV, Psychosis, NMDAR encephalitis

Abstract

Levetiracetam (LEV), an SV2A inhibitor is a widely available anti-epileptic drug that is used to treat a range of partial and generalized seizure and juvenile myoclonic epilepsy. It is generally well tolerated and deemed safe due to the absence of drug-to-drug interaction. Despite its safety, there are adverse effects that can lead to the discontinuation of this anti-seizure medication. Some of the reported infrequent adverse effects are mood-related changes including agitation, depression, anxiety and suicidal ideations that can be observed after initiation or rapid up titration of the medication. The mechanism for this is still unknown but there are certain theories that attempted to determine the association. Risk factors reported were female sex, temporal lobe involvement and history of psychiatric disorder. In this case report, we present a 30-year-old female without history of psychiatric illness diagnosed with anti N-methyl-D-aspartate receptor (NMDAR) encephalitis who presented with seizure and was started on LEV for seizure control. She developed aggression and suicidal ideations secondary to initiation and up-titration of LEV. The symptoms resolved after discontinuation of the said medication.

Metrics

Metrics Loading ...

References

Zhang JF, Piryani R, Swayampakula AK, Farooq O. Levetiracetam‐induced aggression and acute behavioral changes: A case report and literature review. Clin Case Rep. 2022;10.

Ogunsakin O, Tumenta T, Louis-Jean S. Levetiracetam Induced Behavioral Abnormalities in a Patient with Seizure Disorder: A Diagnostic Challenge. Case Rep Psychiatr. 2020;2020:1-4.

Tao K, Chen H, Chen Y, Gu Y, Wang X. Levetiracetam induces severe psychiatric symptoms in people with epilepsy. Seizure. 2022;S1059131122002783.

Dalmau J, Armangué T, Planagumà J. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18:1045-57.

Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res. 2016;176:36-40.

De Bruijn MAAM, Van Sonderen A, Van Coevorden-Hameete MH. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA B R encephalitis. Neurology. 2019;92:e2185-2196.

Trimble MR. Anticonvulsant-Induced Psychiatric Disorders. Drug Saf. 1996;15:159-66.

Krishnamoorthy ES, Trimble MR, Blumer D. The classification of neuropsychiatric disorders in epilepsy: A proposal by the ILAE Commission on Psychobiology of Epilepsy. Epilepsy Behav. 2007;10:349-53.

Trimble M. New Antiepileptic Drugs and Psychopathology. Neuropsychobiology. 1998;38:149-51.

Ketter TA, Malow BA, Flamini R, White SR, Post RM, Theodore WH. Anticonvulsant withdrawal-emergent psychopathology. Neurology. 1994;44:55.

Cramer J. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. 2003;4:124-32.

Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel. Behav Neurol. 2018;2018:1-18.

Lynch DR, Rattelle A, Dong YN, Roslin K, Gleichman AJ, Panzer JA. Anti-NMDA Receptor Encephalitis. Clin Features Basic Mechanisms. 2018;235-60.

Chen Z, Lusicic A, O’Brien TJ, Velakoulis D, Adams SJ, Kwan P. Psychotic disorders induced by antiepileptic drugs in people with epilepsy. Brain. 2016;139:2668-78.

Josephson CB, Engbers JDT, Jette N. Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription. JAMA Neurol. 2019;76:440.

León Ruiz M, Rodríguez Sarasa ML, Sanjuán Rodríguez L. Levetiracetam-induced de novo psychosis: is there a type of patient with epilepsy who is neurostructurally and/or biologically more vulnerable to developing it? Neurol. 2020;35:684-7.

De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: Part II, the Clinical Profile of a Novel Anticonvulsant Drug. CNS Drug Rev. 2007;13:57-78.

Campbell C, McCormack M, Patel S. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia. 2022;63:1563-70.

Molokwu OA, Ezeala-Adikaibe BA, Onwuekwe IO. Levetiracetam-induced rage and suicidality: Two case reports and review of literature. Epilepsy Behav Case Rep. 2015;4:79-81.

Sarangi SC, Kaur N, Tripathi M. Assessment of psychiatric and behavioral adverse effects of antiepileptic drugs monotherapy: Could they have a neuroendocrine correlation in persons with epilepsy? Epilepsy Behav. 2019;100:106439.

Jones RM, Arlidge J, Gillham R, Reagu S, Van den Bree M, Taylor PJ. Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatr. 2011;198:93-8.